Mesa Laboratories, Inc. logo

Mesa Laboratories, Inc.

MLAB

NASDAQHealthcareMedical - Specialties

Previous close

$124.76

+$5.61 · +4.71%

Aug 21, 4:00 PM ET

MLAB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

58

Fair Value

Momentum

48

Neutral

Sentiment

58

Mixed

Risk resilience

52

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
US
CEO
Siddhartha C. Kadia
Listed since
Feb 29, 1984
Employees
717

Market position

Day range

Current $124.76

52-week range

Current $124.76

Open
$117.27
Previous close
$119.15
Volume
160.69K
0.89× average
Average volume
180.62K
Average daily volume
Market cap
698.14M USD
Beta
0.93
Market reference 1
50-day average
$101.72
+22.65% above average
200-day average
$91.9875
+35.63% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
629.45M USD
P/E (TTM)
145.07×
P/B (TTM)
3.74×
P/S (TTM)
2.8×
EV / EBITDA
17.84×
Earnings yield
1.38%
Free cash flow yield
8.12%
Dividend yield
0.51%

Profitability & efficiency

Gross margin
65.99%
Operating margin
9.00%
Net margin
1.92%
Return on equity
3.60%
Return on assets
1.57%
Return on invested capital
2.76%

Financial health

Debt / equity
0.54×
Current ratio
1.72×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends82%7%-69%-145%Gross margin, FY2022: 59.18%Gross margin, FY2023: 61.02%Gross margin, FY2024: 61.64%Gross margin, FY2025: 62.61%Gross margin, FY2026: 63.53%Operating margin, FY2022: 2.55%Operating margin, FY2023: 1.52%Operating margin, FY2024: -125.85%Operating margin, FY2025: 6.78%Operating margin, FY2026: 7.43%Net margin, FY2022: 1.01%Net margin, FY2023: 0.42%Net margin, FY2024: -117.60%Net margin, FY2025: -0.82%Net margin, FY2026: 2.69%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 59.18%. Gross margin FY2023 61.02%. Gross margin FY2024 61.64%. Gross margin FY2025 62.61%. Gross margin FY2026 63.53%. Operating margin FY2022 2.55%. Operating margin FY2023 1.52%. Operating margin FY2024 -125.85%. Operating margin FY2025 6.78%. Operating margin FY2026 7.43%. Net margin FY2022 1.01%. Net margin FY2023 0.42%. Net margin FY2024 -117.60%. Net margin FY2025 -0.82%. Net margin FY2026 2.69%.

Income trends

Revenue

249.13M USD+3.38%

Operating income

18.51M USD+13.31%

Net income

6.71M USD+8.69M USD
Income trends across reported periods301.25M USD92.77M USD−115.71M USD−324.2M USDRevenue, FY2022: 184.34M USDRevenue, FY2023: 219.08M USDRevenue, FY2024: 216.19M USDRevenue, FY2025: 240.98M USDRevenue, FY2026: 249.13M USDOperating income, FY2022: 4.7M USDOperating income, FY2023: 3.32M USDOperating income, FY2024: −272.08M USDOperating income, FY2025: 16.34M USDOperating income, FY2026: 18.51M USDNet income, FY2022: 1.87M USDNet income, FY2023: 930K USDNet income, FY2024: −254.25M USDNet income, FY2025: −1.97M USDNet income, FY2026: 6.71M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 184.34M USD. Revenue FY2023 219.08M USD. Revenue FY2024 216.19M USD. Revenue FY2025 240.98M USD. Revenue FY2026 249.13M USD. Operating income FY2022 4.7M USD. Operating income FY2023 3.32M USD. Operating income FY2024 −272.08M USD. Operating income FY2025 16.34M USD. Operating income FY2026 18.51M USD. Net income FY2022 1.87M USD. Net income FY2023 930K USD. Net income FY2024 −254.25M USD. Net income FY2025 −1.97M USD. Net income FY2026 6.71M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue249.13M USD240.98M USD216.19M USD219.08M USD184.34M USD
Cost of goods sold90.86M USD90.11M USD82.94M USD85.39M USD75.25M USD
Gross profit158.27M USD150.87M USD133.25M USD133.69M USD109.09M USD
Research and development20.31M USD19.52M USD19.3M USD20.49M USD15.77M USD
Selling, general, and administrative119.45M USD115.02M USD111.49M USD109.88M USD88.62M USD
Operating expenses139.76M USD134.53M USD405.33M USD130.37M USD104.39M USD
Interest expense10.69M USD11.86M USD5.7M USD4.77M USD3.89M USD
Depreciation and amortization23.27M USD24.53M USD31.57M USD33.13M USD25.07M USD
Operating income18.51M USD16.34M USD−272.08M USD3.32M USD4.7M USD
Net income6.71M USD−1.97M USD−254.25M USD930K USD1.87M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+257.45%
11 comparable reports
Latest EPS result
2.68
Estimate 2.63 · Beat by 1.90%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates3.22.561.911.27Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 4, 2025: actual 2.67, estimate 1.41, surprise +89.36%, Beat. Q2 2025, reported May 28, 2025: actual 2.23, estimate 2.75, surprise -18.91%, Miss. Q3 2025, reported Aug 5, 2025: actual 2.32, estimate 2.46, surprise -5.69%, Miss. Q4 2025, reported Nov 6, 2025: actual 1.76, estimate 2.3, surprise -23.48%, Miss. Q1 2026, reported Feb 3, 2026: actual 3.07, estimate 1.4, surprise +119.29%, Beat. Q2 2026, reported May 27, 2026: actual 2.76, estimate 2.09, surprise +32.06%, Beat. Q3 2026, reported Aug 10, 2026: actual 2.68, estimate 2.63, surprise +1.90%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.59, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates67.82M64.19M60.56M56.93MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 4, 2025: actual 62.84M USD, estimate 61.53M USD, surprise +2.12%, Beat. Q2 2025, reported May 28, 2025: actual 62.14M USD, estimate 61.9M USD, surprise +0.38%, Beat. Q3 2025, reported Aug 5, 2025: actual 59.54M USD, estimate 60.4M USD, surprise -1.42%, Miss. Q4 2025, reported Nov 6, 2025: actual 60.74M USD, estimate 60.73M USD, surprise +0.01%, Beat. Q1 2026, reported Feb 3, 2026: actual 65.13M USD, estimate 63.23M USD, surprise +2.99%, Beat. Q2 2026, reported May 27, 2026: actual 63.72M USD, estimate 65.21M USD, surprise -2.28%, Miss. Q3 2026, reported Aug 10, 2026: actual 60.14M USD, estimate 60.87M USD, surprise -1.20%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 61.63M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

8 ratings
Strong buy00%
Buy338%
Hold563%
Sell00%
Strong sell00%

MLAB peers

ETFs holding MLAB

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research MLAB

research.disclaimer